Healthcare Global Enterprises Ltd's Q4FY25 Quarter Results
- 25 May 2025
Result Summary
- Healthcare Global Enterprises Ltd reported a 11.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 11.9%.
- Its expenses for the quarter were down by 16.2% QoQ and up 9.7% YoY.
- The net profit increased 202.7% QoQ and increased 315.2% YoY.
- The earnings per share (EPS) of Healthcare Global Enterprises Ltd stood at 1.5 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 499.68 | 563.21 | 446.36 | -11.3% | 11.9% |
Total Expenses | 475.42 | 567.41 | 433.22 | -16.2% | 9.7% |
Profit Before Tax | 28.16 | -4.20 | 13.14 | -770.5% | 114.3% |
Tax | 4.76 | -11.05 | 7.48 | -143.1% | -36.4% |
Profit After Tax | 23.46 | 7.75 | 5.65 | 202.7% | 315.2% |
Earnings Per Share | 1.50 | 0.50 | 0.60 | 200.0% | 150.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Healthcare Global Enterprises Ltd (HCG) operates within the healthcare industry, specializing in cancer care and precision medicine. The company is renowned for its network of cancer care centers across India, offering a range of services including diagnostics, treatment, and follow-up care. HCG's focus is on integrating advanced technology and research to provide comprehensive cancer treatment. As of the data available up to October 2023, HCG has been actively expanding its network and enhancing its service offerings to ensure accessibility and quality care for patients. Any specific recent developments within the company post this period are not available in the current dataset.
Revenue
During Q4FY25, Healthcare Global Enterprises Ltd reported a total income of ₹499.68 crores, representing a decrease of 11.3% compared to the previous quarter (Q3FY25) when the total income was ₹563.21 crores. However, on a year-over-year basis, the total income increased by 11.9% from ₹446.36 crores in Q4FY24. The quarter-over-quarter decline in revenue contrasts with the annual growth, indicating variations in revenue performance across different quarters.
Profitability
In Q4FY25, the company's profit before tax (PBT) was ₹28.16 crores, which is a significant improvement over the previous quarter's loss of ₹4.20 crores. Compared to Q4FY24, the PBT showed an increase from ₹13.14 crores, marking a 114.3% year-over-year growth. The tax expense for Q4FY25 was ₹4.76 crores, showing a notable change from a tax credit in Q3FY25 of ₹11.05 crores and a decrease from the tax expense of ₹7.48 crores in Q4FY24. Consequently, the profit after tax (PAT) in Q4FY25 was reported at ₹23.46 crores, compared to ₹7.75 crores in Q3FY25 and ₹5.65 crores in Q4FY24, reflecting a substantial improvement both quarter-over-quarter and year-over-year.
Operating Metrics
The earnings per share (EPS) for Q4FY25 stood at ₹1.50, a considerable increase from ₹0.50 in Q3FY25 and ₹0.60 in Q4FY24, demonstrating significant growth in shareholder value over these periods. Total expenses for Q4FY25 were ₹475.42 crores, which is a decrease of 16.2% from Q3FY25's expenses of ₹567.41 crores, but a 9.7% increase compared to Q4FY24's expenses of ₹433.22 crores. This fluctuation in expenses coupled with revenue changes has impacted the profitability metrics significantly. Key financial ratios and other operational metrics are not provided in the dataset, thus limiting further detailed analysis in this section.